Insys submits NDA for Buprenorphine Sublingual Spray

Insys Therapeutics Inc. (NASDAQ:INSY) submitted an NDA to FDA for Buprenorphine Sublingual Spray for the management of moderate to severe acute pain. The product has met the primary endpoint in a Pha...